Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
At 50 Cents a Pill, Allergy Drug Could Best $1000 Sovaldi, Harvoni

Published today in the journal Science Translational Medicine, researchers from the National Institutes of Health (NIH) reported chlorcyclizine prevented hepatitis C infection in a petri dish and in humanized mice. They said it was effective and did and did not produce any significant cell toxicity when given along with existing drugs to treat hepatitis C.

Published
09 April 2015
From
Healthline
Abstracts Have Been Posted: International Liver Congress™ 2015 of the European Association for the Study of the Liver (EASL)

Abstracts for The International Liver Congress™ 2015 for the 50th annual meeting of the European Association for the Study of the Liver (EASL) are now available.

Published
09 April 2015
From
HCV New Drugs Research
WHO Issues Guideline For Manufacturers Of Generic Hepatitis C Medicine

The World Health Organization has issued a guidance document on the design of bioequivalence studies for a leading hepatitis C medicine. Generic drug companies seeking prequalification by the WHO need to demonstrate that their generic version is equivalent to the originator drug.

Published
08 April 2015
From
Intellectual Property Watch
Global hepatitis B epidemic treatable at cost of just $36 per patient per year

Large-scale production of generic entecavir could cut the cost of first-line hepatitis B virus (HBV) therapy to just US$36 per patient per year, according to a study published

Published
08 April 2015
By
Michael Carter
End-stage liver disease is a concern for people with HIV and hepatitis B or C co-infection

People with HIV and hepatitis B or C virus co-infection are more likely to progress to end-stage liver disease (ESLD), or liver failure, than those with HIV

Published
07 April 2015
By
Liz Highleyman
Alert: Serbia is losing harm reduction

The situation with harm reduction in Serbia is getting increasingly alarming after withdrawal of the Global Fund. Three organizations doing HR programs in Serbia for more than a decade are struggling to maintain services. We want a different future for their beneficiaries. ""Please use your communication with donors to put Serbia back as eligible for funding the harm reduction programs - we keep knocking on closed doors. The EU is the biggest donor here and has no health programs whatsoever; as for other donors, we are ineligible whomever we approach, and keep losing on relevance to the calls,“ says Miodrag Atanasjevic, NGO Veza, Belgrade, Serbia.

Published
02 April 2015
From
Eurasian Harm Reduction Network
Cannabis use reduces risk of insulin resistance in people with HIV/HCV co-infection

Cannabis use is associated with a reduced risk of insulin resistance in people with HIV and hepatitis C virus (HCV) co-infection, French investigators report in the online

Published
02 April 2015
By
Michael Carter
Oral hepatitis B vaccine could become a reality

In a new study, researchers report progress toward perfecting a radical new method of producing vaccines using genetically modified corn. The approach could lead to an oral hepatitis B vaccine that requires no refrigeration and costs less than $1 per dose to manufacture.

Published
01 April 2015
From
Medical Xpress
Cipla announces the launch of generic drug Sofosbuvir in India under the brand name ‘Hepcvir`

Following the non-exclusive licensing agreement signed with Gilead Sciences in September last year, to manufacture and market chronic hepatitis C medicines, Cipla is now all set to make the drug Sofosbuvir available to Indian patients in a week’s time. The availability of product in other markets is subject to approvals from the regulatory authorities in respective countries.

Published
31 March 2015
From
Cipla press release
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the Treatment of Genotype 2 Chronic Hepatitis C

Primarily due to HCV, Japan has one of the highest rates of liver cancer of any industrialized country. Of the more than one million people chronically infected with HCV, 20-30 percent have the genotype 2 strain of the virus.

Published
31 March 2015
From
Gilead press release

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.